IntelGenx Corp., an oral drug delivery company, announced that the United States Patent and Trademark Office has issued U.S. Patent 10,828,254, entitled “Oral film formulation for modulating absorption profile”. The patent covers a novel oral film dosage technology platform for modulating the in vivo absorption profile of a sublingually- or buccally-administered active ingredient. This novel proprietary technology is suitable for cannabis-containing oral films, especially for THC oral film dosage forms. The issued patent will provide intellectual property protection in the United States for IntelGenx’s novel technology used in the formulation of its future products, through 2038.
“This patent issuance adds to the formidable intellectual property estate that we are building for our film technologies around the globe,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “This novel technology, which is applicable to THC-containing oral films, represents a significant commercial opportunity for IntelGenx, and we will be actively marketing this novel technology in the United States for a wide variety of active ingredients.”
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as VevaDermTM, its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.